NCT02401139CompletedPhase 1
Ketamine Therapy Among Patients With Treatment-resistant Depression: a Randomised, Double-blind, Placebo-controlled Trial: Pilot Phase
The University of New South Wales2 sites in 1 country10 target enrollmentStarted: March 2015Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 10
- Locations
- 2
- Primary Endpoint
- Montgomery Asberg Depression Rating Scale for Depression (MADRS)
Study Overview
Brief Summary
This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Treatment arm
Active Comparator
Ketamine
Intervention: Ketamine (Drug)
Placebo arm
Placebo Comparator
Placebo
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Montgomery Asberg Depression Rating Scale for Depression (MADRS)
Time Frame: 4 weeks
Secondary Outcomes
No secondary outcomes reported
Investigators
Colleen Loo
Professor
The University of New South Wales
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 2
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of DepressionMajor Depressive DisorderNCT06559826Icahn School of Medicine at Mount Sinai70
Unknown
Phase 4
Clinical Trial of the Use of Ketamine in Treatment Resistant DepressionDepressive Disorder, Treatment-ResistantNCT02610712National Institute of Neurology and Neurosurgery, Mexico20
Completed
Not Applicable
A Naturalistic Study of Ketamine for Treatment Resistant Mood DisordersTreatment Resistant DepressionBipolar DepressionKetamineMajor Depressive DisorderNCT04226963Medical University of Gdansk80
Completed
Phase 2
A Study of Ketamine in Patients With Treatment-resistant DepressionMajor Depressive DisorderNCT01627782Janssen Research & Development, LLC68
Recruiting
Phase 4
Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)Ketamine Adverse ReactionNCT04490031Universiti Kebangsaan Malaysia Medical Centre140